Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Molecular Partners (SIX/NASDAQ: MOLN) will present corporate and clinical updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. CEO Patrick Amstutz will speak on Thursday, January 15, 2026 at 10:30–11:10 AM PT (19:30–20:10 CET) at the Westin St. Francis.
A live webcast of the presentation will be available via the company website under the Events tab. The presentation will cover the company’s latest developments and 2025 outlook.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MOLN gained 1.18%, reflecting a mild positive market reaction. Argus tracked a peak move of +15.2% during that session. This price movement added approximately $2M to the company's valuation, bringing the market cap to $164M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: INO up 12.55%, AVTX up 1.32%, NKTX and ACTU down, GNLX flat. No clear sector-wide direction relative to MOLN.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Advisory board formation | Positive | +4.7% | Formed SAB to guide development of DLL3 and mesothelin Radio-DARPins. |
| Nov 12 | Clinical data update | Positive | +2.5% | Presented new human imaging and mechanism data for DLL3 Radio-DARPin MP0712. |
| Nov 03 | Preclinical data presentation | Positive | +12.4% | Reported preclinical proof-of-concept data for logic-gated CD3 Switch-DARPin. |
| Nov 03 | Clinical conference update | Positive | +12.4% | Planned updated Phase 1/2a MP0533 data presentation at ASH Annual Meeting. |
| Oct 30 | Earnings and pipeline | Positive | -3.6% | Q3 2025 financials with cash runway to 2028 and multiple trial updates. |
Recent news flow has mostly seen positive scientific or strategic updates followed by positive price reactions, with Q3 results the main negative divergence.
Over the last few months, Molecular Partners reported several R&D and financial milestones. On Oct 30, 2025, Q3 results highlighted cash runway into 2028 alongside ongoing clinical work, but shares fell. Subsequent updates on MP0533 and Radio-DARPins, including new data and advisory board formation between Nov 3 and Dec 11, 2025, were followed by gains of up to 12.42%. Today’s J.P. Morgan conference appearance fits into this pattern of active clinical and strategic communication with investors.
Market Pulse Summary
This announcement highlights Molecular Partners’ participation at the 44th Annual J.P. Morgan Healthcare Conference from January 12–15, 2025, with a company presentation on January 15. It fits a broader pattern of active communication around clinical and strategic milestones seen since October 2025. Investors may focus on any qualitative updates to the 2025 outlook, pipeline timelines, and cash runway previously discussed in Q3 results and subsequent clinical news.
Key Terms
dar-pin therapeutics medical
AI-generated analysis. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco, CA, USA.
Chief Executive Officer Patrick Amstutz will present on Thursday, January 15 at 10:30AM-11:10AM PT (19:30-20:10 CET) at the Westin St. Francis San Francisco, CA, USA.
A webcast will be accessible on the Molecular Partners website, under the Events tab.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners’ reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners’ ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential that Molecular Partners’ product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ intellectual property position; Molecular Partners’ ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners’ actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
When will Molecular Partners (MOLN) present at the J.P. Morgan Healthcare Conference?
Where and when is the 44th Annual J.P. Morgan Healthcare Conference taking place?
Who from Molecular Partners will present at the MOLN session on January 15, 2026?
How can investors watch the Molecular Partners (MOLN) presentation webcast?
What topics will Molecular Partners (MOLN) cover at the January 15 presentation?
What time is the Molecular Partners webcast in Central European Time (CET)?
